Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy Non STE ACS
Advertisements

Acute MI treatment Roger Suss MD CCFP(EM) Lecturer Dept of Family Medicine University of Manitoba.
Risk stratification and medical management of NSTE-ACS (UA/NSTEMI )
ACUTE CORONARY SYNDROME Jarrod D. Frizzell, MD, MS Fellow, Cardiovascular Medicine July 10, 2014.
Listening to the Data: Why There’s Room for Improvement in MI Care Heartscape® Consultants Meeting Charles V. Pollack, Jr, MA, MD, FACEP, FAAEM, FAHA Chairman,
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
“ If physicians would read two articles per day out of the six million medical articles published annually, in one year, they would fall 82 centuries behind.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
A.Abdi,M.D. Initial Diagnosis Symptoms ECG Cardiac Biomarkers.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
“Acute Coronary Syndromes: Trials & Tribulations" Will Southern, M.D., M.S. Director of Hospitalist Services Associate Medical Director Weiler Division.
Myocardial Infarction
Chest Pain Dr. Shamim Nassrally BSc (Hons) MB ChB MRCP(UK)
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
ACUTE CORONARY SYNDORME EARLY RISK STRATIFICATION Sarah Jamison March 2003.
Acute Coronary Syndrome. Acute Coronary Syndrome (ACS) Definition of ACS Signs and symptoms of ACS Gender and age related difference in ACS Pathophysiology.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
Exercise Echocardiography Cardiac Issues 2011 Douglass A Morrison, MD, PhD.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
Chest Pain Dr. Shamim Nassrally BSc (Hons) MB ChB MRCP(London) Clinical Teaching Fellow.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
ACUTE CORONARY SYNDROME Jarrod D. Frizzell, MD, MS Fellow, Cardiovascular Medicine July 9, 2015.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Antiplatelet Interventions in Acute Coronary Syndromes.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
LESSON 1 LESSON 1 Establishment of:
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Acute Coronary Syndrome
Atherosclerotic Cardiovascular Heart Disease in Women
CPR in ACUTE CORONARY SYNDROM
Clinical Trial Commentary
Risk Stratification of Chest Pain: Best Practices
Risk stratification in ACS F.Shakib .cardiologigst
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Ischaemic Heart Disease Acute Coronary Syndrome
Dr. Harvey White on behalf of the ACUITY investigators
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Unstable Angina and Non–ST Elevation Myocardial Infarction
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
Section F: Clinical guidelines
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
The European Society of Cardiology Presented by RJ De Winter
on behalf of the ACUITY investigators
Acute Coronary Syndrome (1)
What oral antiplatelet therapy would you choose?
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Acute Coronary Syndrome David Aymond, MD

ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS is a spectrum: UA vs NSTEMI vs STEMI -Unstable angina/NSTEMI: angina that is new onset, crescendo, or at rest; typically <30mns + TWI or ST- depression *NSTEMI is term used with this history/EKG with slightly elevated Troponin/CK-MB -STEMI: Angina at rest >30mns with ST elevations and markedly elevated enzymes (2x upper limit of NL)

How to Triage (ACC/AHA 2007 Guidelines update for UA/NSTEMI) -This is based solely on Pre-test Probability, these the risk of short term death or non fatal MI FeatureHigh (any)Intermediate (no high features) Low (no high/inter. Features) HistoryChest/arm pain like prior angina; h/o CAD (inc MI); TRS > 3; Age > 75 Chest or L arm pain Age>70 Male, DM Atypical Sx ExamHoTN, diapho, CHF, MRPAD or CVDPain rep. on palpation ECGNew STD (>1mm), TWI in mult. Leads Old Qw, STD (.5-.9mm), TWI TWF/TWI (<1m) in dominant leads Biomarkers+ Tn or CK-MBNormal

Triage If hx and initial EKG and biomarkers non-dx, repeat ECG and biomarkers 12 h later If low likelihood, CE remain NL and remain pain free, have r/o MI; but if clinical suspicion high based on Hx still need to evaluate for UA/inducible ischemia: if pt has no historical/exam that’s IM/High, can do ETT as outPt w/in 72 hrs ( 0 % mortality,.5% MI) (Ann Emerg Med 2006; ) If has IM RF’s for ACS based on hx, admit and evaluate If ECG or biomarker abnl or high likelihood ACS, then admit and evaluate

Conservative vs Early Invasive Approach Conservative approach taken if low risk (- Tn, no ST dep, TRS 0-2, and NO CHF); conservative approach means medical Rx with Pre-d/c stress test; angio only if strongly + ETT; this is SOC in Unstable Angina Early Invasive approach taken if high risk (+TN, ST dep, TRS> 3, s/s CHF); early invasive approach means Med Rx + angiography w/in hrs; this is SOC for NSTEMI Med Rx=EMONACAGB

Medical Management Enoxaparin: 1mg/kg BID; 10% dec death/MI (JAMA 2004;292:89); greatest benefit in CONS strategy Morphine: consider if pulmonary edema or persistent Sx Oxygen: keep SaO2 >90% Nitrates: dec anginal sx, no dec in mortality ASA: mg x 1 crushed/chewed; then /day; 50-70% dec in D/MI (NEJM 1988;319:1105); if ASA allergy, use Clopidogrel Coronary angiography: only if high risk/NSTEMI within hrs Clopidogrel: give w/ ASA 20% dec. CVD/MI/stroke, inc. benefit if given upstream prior to PCI, but need to D/C 5 days prior to CABG (NEJM 2001; 345:494; Lancet 2001; 358:257) ACE-I/ARB: esp if CHF and SBP>100 Glycoprotein IIb-IIIa inhibitors: only if TRS>3 will benefit be increased (JACC 2003; 41:895) Beta-Blockers: PO, titrate to keep HR 50-60; IV if ongoing pain=13% dec in progression to MI (JAMA 1988; 260:2259); contraindicated in hypotension, bradycardia and ADHF

TIMI Risk Score RISK FACTORScoreScore TotalD/MI/UR Age > % > 3 RF for CAD128% Known CAD1313% ASA use in past 7 d1420% Severe Angina (>2 episodes in 24 hrs) 1526% ST deviation > 0.5 mm % + Tn/CK-MB1

GRACE Risk Score GRACE= Global Registry for Acute Coronary Events Very large, multi-national randomized trial When you compare the TIMI, PURSUIT and GRACE risk score for validation of end points, the GRACE is “more advantageous and easier to use; it can categorize a patients risk of death/MI and can help tailor therapy to match the intensity of the patients ACS”

Algorithm for the evaluation and management of patients suspected of having an ACS. Braunwald E et al. Circulation 2000;102: Copyright © American Heart Association